BRAF and neoplasm: Thirty-three patients carried a RAS/BRAF-mutated tumor and were treated with FOLFOX-bevacizumab, and 22 patients had a RAS/BRAF wild-type tumor and were treated with FOLFOX-panitumumab; 18 patients had two or more distant metastases while in the remaining, there was a single metastatic localization.